BACKGROUND The purpose of this study is to examine whether physical disability is associated with faster rate of decline in cognitive function. METHODS A longitudinal population-based cohort of 6,678 initially nondisabled older adults from a biracial urban community was interviewed at 3-year intervals from 1993 to 2012. Cognitive function was assessed using a standardized global cognitive sco...

BACKGROUND What currently appears to be irreversible axonal loss in normal appearing white matter, measured by proton magnetic resonance spectroscopy is of great interest in the study of Multiple Sclerosis. Our aim is to determine the axonal damage in normal appearing white matter measured by magnetic resonance spectroscopy and to correlate this with the functional disability measured by Multip...

It is commonly recognized that proinflammatory cytokines in patients with multiple sclerosis (MS) may increasingly cause inflammation. In this regard, the current study was aimed to shed light on the effectiveness of eight-week Pilates training program at interleukin-18 (IL-18) stage, severity of fatigue and balance as well as physical disability in females with MS. This study was a quasi-exper...

BACKGROUND The effects of treatment in trials with trauma-affected refugees vary considerably not only between studies but also between patients within a single study. However, we know little about why some patients benefit more from treatment, as few studies have analysed predictors of treatment outcome. OBJECTIVE The objective of the study was to examine possible psychosocial predictors of ...

BACKGROUND AND OBJECTIVES In the management of attention-deficit hyperactivity disorder (ADHD) in adults it is important to recognize that individual patients respond to a wide range of methylphenidate doses. Studies with methylphenidate modified release long acting (MPH-LA) in children have reported the need for treatment optimization for improved outcomes. We report the results from a post ho...

BACKGROUND Measurement of disability in rheumatoid arthritis is often used to support treatment decisions and outcome assessments, but is used without reference to the impact of disability on individual patients. OBJECTIVE To develop and validate a scale to measure individual values for functions, which is used to weight the level of an individual patient's functional loss and thus calculate ...

Levomilnacipran (LVM, Fetzima(®)) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including duloxetine, venlafaxine, and desvenlafaxine, it has greater selectivity for inhibiting norepinephrine reupta...